In the quiet of a biology lab at UC San Diego, researchers have enlisted machine learning to do what centuries of traditional experimentation could not: locate the rarest functional DNA sequences hidden within a space of millions of possibilities. Building on prior work mapping the genetic gateways that govern roughly a third of human genes, the team trained AI models to design sequences with species-specific gene activation properties — a feat that compresses what would have been geological timescales of laboratory work into hours. It is a reminder that intelligence, whether biological or art
News-Medical.net
· May 19, 2023
· technology
· 5 min de leitura
High
Apuração: Verificado
UC San Diego researchers use AI to design custom DNA sequences for gene activation
◉
Technology
10947 artigos relacionados
Google Launches Gemini Enterprise for Legal Services
Google News · 100% correspondência
Huang's China Trip Puts Nvidia at Center of U.S.-China Tech Negotiatio…
Barchart · 99% correspondência
Huang Heads to Taiwan as Nvidia Deepens AI Chip Alliance Strategy
Barchart · 99% correspondência
Jensen Huang: From Denny's Busboy to Nvidia CEO Worth $100B+
Yahoo Finance · 99% correspondência
Nvidia's Saudi Arabia chip deal signals diversification beyond U.S. te…
CNBC · 99% correspondência
Cobertura Relacionada
The New York Times · Sep 23
Global Optimism on A.I. Outpaces Western Anxiety, Gallup Poll Shows
A Gallup poll across 37 countries reveals most people express curiosity or excitement about AI rather than fear, contras…
EY · Sep 23 AI shopping agents poised to reshape Australian grocery competition, but consumers demand oversightEY research finds 72% of Australians accept AI gathering grocery prices and deals, but only 2% would let AI complete ent…
SJX Watches · Sep 23 H. Moser & Cie. Off-Grid: Luxury Watchmaker's Offline Smartwatch GambitSwiss luxury watchmaker H. Moser & Cie. released the Off-Grid, a hybrid smartwatch combining mechanical aesthetics with …
Google News · Sep 23 AI Internet Takeover Fears Escalate as Scientists Warn of Potential Swarm ThreatsResearchers are raising concerns about autonomous AI agents potentially compromising internet infrastructure, with some …
Viés e Enquadramento
⚖
Science reporting with neutral tone and minimal bias; presents research findings straightforwardly with appropriate context and future applications.
Bias Direction
center
Confidence
HIGH
Objective scientific reporting with contextual framing that connects AI to broader public awareness before narrowing to specific research application.
Ethical considerations or concerns about synthetic DNA design
Potential risks or limitations of the technology
Competing research or alternative approaches
Industry or commercial implications/concerns
Regulatory framework discussion
Impacto Geopolítico
🌎
UC San Diego AI-driven gene activation research advances synthetic biology capabilities with potential dual-use applications in biotechnology and medicine.
Escalation Risk
low
Confidence
MED
United States
Global biotechnology sector
International research community
Strengthens U.S. scientific leadership in AI-driven synthetic biology; potential competitive advantage in biotech innovation. May accelerate biotechnology development globally, with implications for which nations lead in gene therapy and synthetic biology markets.
Similar to the early recombinant DNA research era (1970s), where foundational scientific breakthroughs preceded regulatory frameworks and international governance discussions about dual-use research.
Lente Econômica
📈
UC San Diego researchers use AI to design custom DNA sequences for precise gene activation, enabling targeted biotechnology applications with potential therapeutic benefits.
Market Signal
bullish
Confidence
MED
Biotechnology
Pharmaceutical/Drug Development
Medical Devices
Genetic Engineering
Artificial Intelligence/Machine Learning
Healthcare/Gene Therapy
Consumers may eventually benefit from more precise, personalized gene therapies and targeted drug treatments with fewer side effects, though commercialization timelines remain uncertain. Healthcare costs could decrease long-term if treatments become more efficient.
Regulatory bodies (FDA, EMA) may need to establish new frameworks for evaluating AI-designed synthetic DNA sequences and gene therapies. Intellectual property policies around AI-generated genetic designs require clarification. Bioethics oversight of custom gene activation applications will likely intensify.